Patients must have sufficient resolution of any surgical side effects (no active wound healing complications). -Patients must either be initiating or have already started adjuvant hormonal treatment. -
Evidence of a significant uncontrolled concomitant disease of the nervous system, pulmonary, autoimmune, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity.
Patients with serious non-healing wound, ulcer, or bone factor; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Have active poor wound healing (delayed healing, wound infection or fistula)
Any open wound
Subject who has an active or potential infection at the surgical site, or whose surgical wound is defined as a wound classification of CO (Contaminated) or D (Dirty or Infected) based upon the Center for Disease Control and Prevention's wound classification system; and
Has history of wound dehiscence or complications requiring medical intervention within  months of study entry
At least  weeks must have elapsed since any surgeries, with evidence of good wound healing
Evidence of wound dehiscence
At least  weeks must have elapsed since any surgeries, with evidence of completed wound healing
No evidence of a history of wound healing complications prior to study enrollment
Increased risk of wound dehiscence or presence of non-healing wounds
Signs of wound-healing problems or infection at the craniotomy/biopsy site.
Incomplete wound healing
Must not exhibit a non-healing wound or any skin breakdown
Patients must be  weeks or greater, beyond major surgical procedures such as thoracotomy, laparotomy or joint replacement, and must be . weeks or greater, beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc, and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery.
Evidence of inadequate wound healing
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within  weeks or minor surgical procedures within  week before randomization
Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Has evidence of inadequate wound healing.
Subject with an unhealed surgical wound or other clinically significant wound
Major injuries within the past  days prior to start of study treatment with incomplete wound healing
Unhealed surgical wound at time of treatment, or history of unhealed surgical wound for more than  days
Has any condition known to effect wound healing, such as collagen vascular disease
Subjects who have an active clinically serious infection of CTCAE Grade ? or non-healing wound unrelated to the primary Tumor.
The subject has evidence of wound dehiscence
Patient has an unhealed surgical wound
Patients with serious non-healing wound, ulcer, or bone fracture, including history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within  days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within  weeks or minor surgical procedures within  week before randomization
Serious, non-healing wound, ulcer, or bone fracture; patients with any wound requiring surgical intervention (including scalp wounds requiring cranioplasty) will be allowed to resume the study if the wound is clean and without further infection post-surgical intervention
Interval of at least  weeks from any prior neurosurgical resection ( week for intracranial biopsy) to start of study drug; and patient must have adequate wound healing
Patients with serious non-healing wound, ulcer, or untreated bone fracture. This includes a history of abdominal fistula or gastrointestinal perforation within  months prior to Day . Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations until closure.
Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
More than  weeks must have elapsed since an surgical procedure at the time the patient receives the preparative regimen due to the inhibition of wound healing observed with VEGFR targeting angiogenesis inhibitors
Evidence of significant uncontrolled concomitant diseases, such as ocular toxicities, diabetes, cardiovascular disease; nervous system, renal, hepatic, endocrine, or gastrointestinal disorders; autoimmune disease, or a serious non-healing wound or fracture
Cutaneous squamous cell carcinomas (SCC) lesions identified at baseline must be excised; adequate wound healing is required prior to study entry; baseline skin exam is required for all patients
Any medical condition that requires intact wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the investigational agent
Impaired wound healing or other extremity complications due to diabetes mellitus in subjects whose Study Lesions are located in an extremity
Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study enrollment
Evidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
Patients with serious non-healing wound, ulcer or bone fracture; this includes history of abdominal fistula or intra-abdominal abscess within  months; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
Incomplete wound healing
Patients who have not recovered from the surgical resection of rectal cancer such as wound dehiscence, non-healing wound, wound infection and fistula
Primary closure of wound
Currently has a condition that could compromise or complicate wound healing. Note, obesity alone is not an exclusion. All surgical risk factors (obesity, diabetes, smoking history, and prior radiation) should be considered in totality for proper subject selection
Expected primary wound closure performed at the time at surgery
Any of the following breast cancer surgery complications; persistent seroma requiring aspiration, wound dehiscence, infection, prolonged drain output, lymphedema
Any infection or unhealed wound of the radiotherapy portal areas, or generalized dermatitis
